At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 26 enrolled
Drug / intervention
Trimetazidine +1 moredrug
Likely dose
Trimetazidine 35 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension Patients in National Cardiovascular Center Harapan Kita Hospital Indonesia
In Brief
A Phase 3 clinical trial evaluating Trimetazidine and Placebo oral capsule for Precapillary Pulmonary Hypertension. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The study will evaluate the effect of trimetazidine versus placebo in addition to standard pulmonary arterial hypertension regime on right ventricular function in pulmonary arterial hypertension patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrecapillary Pulmonary Hypertension
CountriesIndonesia
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartSep 2017
Primary CompletionNov 2018
Study CompletionDec 2018
TodayJul 2026
First PostedSep 6, 2017
Enrollment StartSep 10, 2017
Primary CompletionNov 1, 2018
Study CompletionDec 14, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.8 years ago
Interventions
Trimetazidinedrug
The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
Placebo oral capsuledrug
The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.